Skye Bioscience completes enrollment of Phase 2a trial of SBI-100

Skye Bioscience has dosed 56 patients using SBI-100 Ophthalmic Emulsion in its Phase 2a study and completed final study visits for all patients. SBI-100 OE is a cannabinoid receptor type 1 agonist administered topically onto the eye and is being developed to address unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension. All treated patients completed the study, with no early discontinuations due to adverse events. Topline data for the entire study will be available in Q2.